C
Catalyst Pharmaceuticals, Inc. CPRX
$20.03 $0.150.76%
Recommendation
Hold
Prev Close
$19.88
Volume
193,301
Avg Vol (90D)
1,065,803
Market Cap
$2.36B
Dividend & Yield
--
52-Week Range
$11.78 - $21.67
P/E (TTM)
36.81
EPS (TTM)
$0.54
My Lists My Alerts
Report
Rating
Reward
B
Good
Risk
C-
Fair
Rating Factors
Growth Index
Fair
Efficiency Index
Excellent
Solvency Index
Excellent
Total Return Index
Good
Volatility Index
Fair
Dividend Index
--
Headlines
CPRX or STVN: Which Is the Better Value Stock Right Now?
10/4/2024 - Zacks Investment Research
Catalyst (CPRX) is on the Move, Here's Why the Trend Could be Sustainable
10/2/2024 - Zacks Investment Research
Catalyst (CPRX) Upgraded to Buy: What Does It Mean for the Stock?
10/1/2024 - Zacks Investment Research
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
10/1/2024 - Globe Newswire
Point72 Asset Management L.P. Has $9.58 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
10/1/2024 - MarketBeat - AP News
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Dimensional Fund Advisors LP
9/30/2024 - MarketBeat - AP News
American Century Companies Inc. Sells 94,950 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
9/28/2024 - MarketBeat - AP News
Profund Advisors LLC Sells 41,182 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
9/26/2024 - MarketBeat - AP News
Catalyst Pharmaceuticals: High Valuation Amid Weak Long-Term Prospects (Rating Downgrade)
9/24/2024 - SeekingAlpha
Catalyst Pharmaceuticals: DyDo approved to commercialize FIRDAPSE in Japan
9/24/2024 - The Fly
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan
9/24/2024 - Globe Newswire
Catalyst Pharmaceuticals (CPRX, $20.49) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 23, 2024
9/24/2024 - Tickeron - Stocks
Catalyst Pharmaceuticals (CPRX, $20.79) RSI Indicator left the overbought zone on September 20, 2024
9/21/2024 - Tickeron - Technical Analysis
Catalyst Pharmaceuticals (CPRX, $21.36) Moving Average Convergence Divergence (MACD) Histogram turned positive on September 19, 2024
9/20/2024 - Tickeron - Stocks
Catalyst Pharmaceuticals (CPRX, $21.36) RSI Indicator left the overbought zone on September 19, 2024
9/20/2024 - Tickeron - Stocks
Catalyst Pharmaceuticals (CPRX, $21.36) price may drop as it broke higher Bollinger Band on Sep 19, 2024
9/20/2024 - Tickeron - Stocks
Catalyst Pharmaceuticals (CPRX, $20.44) Stochastic Oscillator left the overbought zone on September 16, 2024
9/17/2024 - Tickeron - Stocks
Catalyst Pharmaceuticals (CPRX, $20.22) entered Uptrend as Momentum indicator ascends above 0 level on Sep 13, 2024
9/14/2024 - Tickeron - Stocks
Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update
9/12/2024 - Globe Newswire
Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?
9/6/2024 - Zacks Investment Research
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
9/2/2024 - Zacks Investment Research
Catalyst Pharmaceuticals (CPRX, $19.98) Moving Average Convergence Divergence (MACD) Histogram turned negative on August 29, 2024
8/30/2024 - Tickeron - Technical Analysis
Don't Ignore The Insider Selling In Catalyst Pharmaceuticals
8/24/2024 - Simply Wall St
Catalyst Pharmaceuticals (CPRX, $20.32) RSI Indicator left the overbought zone on August 23, 2024
8/24/2024 - Tickeron - Stocks
Insider Sale at Catalyst Pharmaceuticals Inc (CPRX): Chief Operating & Scientific Officer ...
8/22/2024 - GuruFocus
Income Statement
Total Revenue (TTM)
$434.48M
EBITDA (TTM)
$122.45M
EBIT (TTM)
$85.88M
Net Income (TTM)
$68.15M
Balance Sheet
Total Assets (Q)
$706.36M
Total Debt (Q)
$3.38M
Total Liabilities (Q)
$97.71M
Book Value Per Share (Q)
$5.14
Cash Flow
Cash from Operations (TTM)
$196.84M
Cash from Investing (TTM)
-$131.34M
Cash from Financing (TTM)
$131.41M
Net Change in Cash (TTM)
$196.91M
Filings
Filing Date
Wednesday, August 7, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Week of Nov 4 and 8 (est)
Price History
Loading...
Beta
0.68
7-Day Total Return
0.15%
30-Day Total Return
-3.42%
60-Day Total Return
22.81%
90-Day Total Return
20.88%
Year to Date Total Return
17.07%
1-Year Total Return
65.67%
2-Year Total Return
57.10%
3-Year Total Return
275.80%
5-Year Total Return
312.99%
52-week Low
Oct 04, 2023 - $11.78
52-week High
Sep 20, 2024 - $21.67
Valuation
Market Cap
$2.36B - Mid Cap
Enterprise Value
$1.99B
Price/Sales (TTM)
5.70
Price/Book (Q)
3.87
Dividends and Shares
Shares Outstanding
124.66M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.catalystpharma.com
Phone Number
305 420 3200
Address
355 Alhambra Circle
Coral Gables, FL 33134
Country
United States
Year Founded
2002
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and... more
NASDAQ 10/04/2024 1:52PM Eastern Quotes delayed
Weiss Ratings